Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray et al.

Primary endpoint

Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.

Population

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF); n=4744

doi:10.1056/NEJMoa1911303

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.

cardiology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of DAPA-HF are confirming the original effect size in real-world data.

cardiology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, quadruple therapy (ACEi/ARNI + BB + MRA + SGLT2i) will be the default HFrEF regimen in US registries.

cardiology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT01035255

0.1026

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT03057977

0.1076

· 3 claims

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

NCT01471522

0.2101

· 3 claims

Initial Invasive or Conservative Strategy for Stable Coronary Disease

NCT02062593

0.2181

· 3 claims

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

NCT01692379

0.2223

· 3 claims

Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke

NCT00829166

0.2307

· 3 claims

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer